Probabilistic Study of the Effect of Anti-Epileptic Drugs Under Uncertainty: Cost-Effectiveness Analysis

被引:1
作者
Barrachina-Martinez, Isabel [1 ]
Navarro-Quiles, Ana [2 ]
Ramos, Marta [1 ]
Romero, Jose-Vicente [3 ]
Rosello, Maria-Dolores [3 ]
Vivas-Consuelo, David [1 ]
机构
[1] Univ Politecn Valencia, Res Ctr Hlth Econ & Management, Dept Econ & Social Sci, INECO, Edificio 7J,Camino Vera S-N, Valencia 46022, Spain
[2] Univ Valencia, Dept Stat & Operat Res, Dr Moliner 50, Burjassot 46100, Spain
[3] Univ Politecn Valencia, Inst Univ Matemat Multidisciplinar, Edificio 8G,Camino Vera S-N, Valencia 46022, Spain
关键词
anti-epileptic drugs; uncertainty quantification; first probability density function; random variable transformation technique; Markov model; EPILEPSY; RETIGABINE;
D O I
10.3390/math8071120
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Epilepsy is one of the most ancient diseases. Despite the efforts of scientists and doctors to improve the quality of live of epileptic patients, the disease is still a mystery in many senses. Anti-epileptic drugs are fundamental to reduce epileptic seizures but it have some adverse effects, which influence the quality of life outcomes of the patients. In this paper, we study the effectiveness of anti-epileptic drugs taking into account the inherent uncertainty. We establish a model, which allows to represent the natural history of epilepsy, using Markov chains. After randomizing the mathematical model, we compute the first probability density function of the solution stochastic process applying the random variable transformation technique. We also take advantage of this method to determine the distribution of some key quantities in medical decision, such as the time until a certain proportion of the population remains in each state and the incremental cost-effectiveness ratio. The study is completed computing all these quantities using data available in the literature. In addition, regarding the incremental cost-effectiveness ratio, different third generation anti-epileptic treatments are compared with the Brivaracetam, a new third generation anti-epileptic drug.
引用
收藏
页数:19
相关论文
共 25 条
  • [11] European Medicines Agency (EMA), EPARS AUTH MED PROD
  • [12] Garcia Ramos R., 2011, NEUROLOGIA, V26, P548, DOI [10.1016/j.nrleng.2011.03.00421757265, DOI 10.1016/J.NRLENG.2011.03.00421757265]
  • [13] Instituto Nacional de Estadistica (INE), POBL EST ESP
  • [14] The decision rules of cost-effectiveness analysis
    Karlsson, G
    Johannesson, M
    [J]. PHARMACOECONOMICS, 1996, 9 (02) : 113 - 120
  • [15] Retigabine as add-on treatment of refractory epilepsy a cost-utility study in a Swedish setting
    Kristian, B.
    Wachtmeister, K.
    Stefan, F.
    Forsgren, L.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (06): : 419 - 426
  • [16] Magiorkinis E., 2011, HALLMARKS HIST EPILE, P131
  • [17] The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: A systematic review and indirect comparison
    Martyn-St James, Marrissa
    Glanville, Julie
    McCool, Rachael
    Duffy, Steve
    Cooper, James
    Hugel, Pierre
    Lane, Peter W.
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2012, 21 (09): : 665 - 678
  • [18] Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population
    Mulhern, Brendan
    Rowen, Donna
    Snape, Dee
    Jacoby, Ann
    Marson, Tony
    Hughes, Dyfrig
    Baker, Gus
    Brazier, John
    [J]. EPILEPSY & BEHAVIOR, 2014, 36 : 12 - 17
  • [19] Cost-effectiveness analysis in the economic assessment of health interventions
    Prieto, L
    Sacristán, JA
    Antoñanzas, F
    Rubio-Terrès, C
    Pinto, JL
    Rovira, J
    Grupo, ECOMED
    [J]. MEDICINA CLINICA, 2004, 122 (13): : 505 - 510
  • [20] Sacristán J.A., 2002, Gac Sanit, V16, P334